{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:56:37Z","timestamp":1778536597270,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2011,11,28]],"date-time":"2011-11-28T00:00:00Z","timestamp":1322438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this study is to investigate the potential in vivo antiplatelet and thromboprotective properties of the antihypertensive drug losartan in mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Aggregometry studies were performed on platelets obtained from mice administered losartan for 5 days, via tail vein to examine the ex vivo effects (dose dependence) of this agent and to select an appropriate dose for the in vivo studies. Next, the tail bleeding time test and the time for occlusion in a carotid artery injury thrombosis model (ferric chloride) were also performed to assess the in vivo effects of losartan treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>These data indicate that the antihypertensive agent losartan exerts dose-dependent inhibition of the thromboxane receptor-mediated (U46619\/agonist)-induced platelet aggregation ( ex vivo), whereas it produced no detectable effects on aggregation triggered by adenosine diphosphate or the thrombin receptor activating peptide 4. Findings from the in vivo analysis revealed that tail bleeding time of losartan-treated mice was not different from vehicle-treated mice. On the other hand, in the carotid artery injury thrombosis model, it was found that the losartan-treated mice had significantly longer time for occlusion in comparison with those treated with vehicle control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      These findings provide evidence that administration of the antihypertensive drug losartan into live mice produces thromboxane A\n                      <jats:sub>2<\/jats:sub>\n                      receptor\u2013specific antiplatelet effects. Furthermore, interestingly, this antiplatelet activity appears to translate into thromboprotective properties, without resulting in a bleeding phenotype. Consequently, aside from its potential use as an antithrombotic agent, losartan\u2019s chemistry may provide a \u201cblueprint\u201d for designing or repurposing novel derivatives which may have the potential to serve as an antiplatelet and thromboprotective agents but are deprived of the usually concomitant bleeding adverse effects.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1074248411425491","type":"journal-article","created":{"date-parts":[[2011,11,29]],"date-time":"2011-11-29T12:44:49Z","timestamp":1322570689000},"page":"308-314","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Characterization of the\n                    <i>In Vivo<\/i>\n                    Antiplatelet Activity of the Antihypertensive Agent Losartan"],"prefix":"10.1177","volume":"17","author":[{"given":"John P.","family":"Murad","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enma V. P.","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold J.","family":"Ting","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi T.","family":"Khasawneh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2011,11,28]]},"reference":[{"key":"bibr1-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011670"},{"key":"bibr2-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198010163031601"},{"key":"bibr3-1074248411425491","doi-asserted-by":"publisher","DOI":"10.5551\/jat.7633"},{"issue":"7","key":"bibr4-1074248411425491","first-page":"887","volume":"70","author":"Coccheri S","year":"2010","journal-title":"With a reappraisal of direct thromboxane inhibitors. Drugs"},{"key":"bibr5-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000251742.71301.16"},{"key":"bibr6-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.09.035"},{"key":"bibr7-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1177\/009127002401102722"},{"key":"bibr8-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20928"},{"key":"bibr9-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2009.195"},{"key":"bibr10-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.09.009"},{"issue":"4","key":"bibr11-1074248411425491","first-page":"715","volume":"51","author":"Ch\u0142opicki S","year":"2000","journal-title":"J Physiol Pharmacol."},{"key":"bibr12-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199917030-00019"},{"key":"bibr13-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.02.007"},{"key":"bibr14-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.04.053"},{"key":"bibr15-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(98)00039-5"},{"issue":"4","key":"bibr16-1074248411425491","first-page":"571","volume":"56","author":"Kaminska M","year":"2005","journal-title":"J Physiol Pharmacol."},{"key":"bibr17-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-180687"},{"key":"bibr18-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M506518200"},{"issue":"13","key":"bibr19-1074248411425491","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0022-3565(24)36715-1","volume":"281","author":"Li P","year":"1997","journal-title":"J Pharmacol Exp Ther."},{"issue":"1","key":"bibr20-1074248411425491","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(24)35282-6","volume":"292","author":"Li P","year":"2000","journal-title":"J Pharmacol Exp Ther."},{"key":"bibr21-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1994.1113"},{"key":"bibr22-1074248411425491","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2000.022"},{"key":"bibr23-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.03.001"},{"key":"bibr24-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00434-9"},{"key":"bibr25-1074248411425491","doi-asserted-by":"crossref","unstructured":"Kim J-S, Lee K-S, Kim Y-I, Tamai Y, Nakahata R, Takami H. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci. Aug 2004;11(6):600\u2013602.","DOI":"10.1016\/j.jocn.2003.10.022"},{"key":"bibr26-1074248411425491","first-page":"1","volume":"10","author":"Bhatt DL","year":"2010","journal-title":"N Engl J Med."},{"key":"bibr27-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.05.013"},{"key":"bibr28-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurpra.2010.08.014"},{"key":"bibr29-1074248411425491","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544080-00003"},{"key":"bibr30-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.132886"},{"key":"bibr31-1074248411425491","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60600-4"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248411425491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1074248411425491","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248411425491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:41:34Z","timestamp":1777394494000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1074248411425491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,28]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1177\/1074248411425491"],"URL":"https:\/\/doi.org\/10.1177\/1074248411425491","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,28]]}}}